Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed)

Tumori

Volumn 83, Issue 1 SUPPL., 1997, Pages

  Cunningham, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; FLUOROURACIL; FOLINIC ACID; RALTITREXED; THYMIDYLATE SYNTHASE;

CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0030977417     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/03008916970831s130     Document Type: Conference Paper

References (8)

1. August D.A., Ottow R.T., Sugarbaker P.H.: Clinical perspectives of human colorectal cancer metastases. Cancer Metastases Rev., 3: 303-324, 1984.
2. Moertel C.G.: Chemotherapy for advanced colorectal cancer. N. Engl. J. Med., 330: 1136-1141, 1994.
3. Ross P., Heron J., Cunningham D.: Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur. J. Cancer, 32A (suppl. 5): S13-S17, 1996.
4. Scheithauer W., Rosen H., Kornek G.V., Sebasta C., Depisch D.: Randomised comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin and cisplatin therapy in patients with advanced colorectal cancer. Br. Med. J., 306: 752-755, 1993.
5. Seitz J.F., Cunningham D., Rath U., Olver I.N., Van Cutsem E., Kerr D., Svensson C., Perez Manga G., Harper P., Zalcberg J., Lowery K., Azab M. for the Tomudex' study group. Final results and survival data of a large randomised trial of 'Tomudex' in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluorouracil plus leucovorin (5FU+LV). Proc. Am. Soc. Clin. Oncol., 15: 201, 1996.
6. Topham C., St. Luke's Hospital, Guildford, UK, personal communication.
7. Zalcberg J., Cunningham D., Green M., Francois E., Van Cutsem E., Schornagel J., Adenis A., Seymour L., Azab M., for the Tomudex' Colorectal Cancer Study Group. The final results of a large phase II study of the potent thymidylate synthase inhibitor Tomudex (ZD 1694) in advanced colorectal cancer. J. Clin. Oncol., 14: 716-721, 1996.
8. Zeneca Ltd., data on file.